Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Last Updated   May 29, 2025

Want to learn how to participate in this trial?

88998377LYM1001

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
    phase 1
  • Sites
    19 Sites
  • Status
    Recruiting

SUMMARY

The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation) and to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).

CONDITIONS

  • Lymphoma, Non-Hodgkin
  • Refractory B-Cell NHL
  • Relapsed B-cell NHL

ELIGIBILITY


Inclusion Criteria:

* Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease
* Participants have measurable disease or meet all requirements for adequate response assessment as defined by the appropriate disease response criteria at screening
* Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participants have a life expectancy of greater than or equal to (>=) 12 weeks
* Be willing and able to adhere to the lifestyle restrictions specified in the protocol


Exclusion Criteria:

* Participant with active or prior history of B-cell NHL involving the central nervous system (CNS) and leptomeningeal involvement
* History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study treatment as malignancies can interfere with study endpoints
* Participant having known allergies, hypersensitivity, or intolerance to the excipients of JNJ-88998377
* Participant had major surgery or had significant traumatic injury within 30 days before first dose of study treatment or has not recovered from surgery and must not have major surgery planned during the time the participant is receiving study treatment
* Participant received an autologous stem cell transplant less than or equal to (<=) 3 months before the first dose of study treatment


Inclusion Criteria:

* Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease
* Participants have measurable disease or meet all requir

More...

DETAILS

LOCATIONS

Locations in:
Japan, Taiwan, Türkiye, Italy, South Korea, China, Poland
Country (7) City or Province (19) Status
Japan Tokyo The Cancer Institute Hospital of JFCR
RECRUITING
Taiwan Taipei National Taiwan University Hospital
RECRUITING
Taiwan Taoyuan Linkou Chang Gung Memorial Hospital
RECRUITING
Türkiye Ankara Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
RECRUITING
Türkiye Ankara Ankara University Medical Faculty
RECRUITING
Türkiye Istanbul Koc University Medical Faculty
RECRUITING
Italy Bologna A O U Sant Orsola Malpighi
RECRUITING
South Korea Seoul Samsung Medical Center
RECRUITING
China Beijing Beijing Cancer Hospital
RECRUITING
China Hang Zhou Shi The First Affiliated Hospital Zhejiang University College of Medicine
RECRUITING
China Shanghai Fudan University Shanghai Cancer Center
RECRUITING
China Tianjin Tianjin Medical University Cancer Institute and Hospital
RECRUITING
Japan Kashiwa National Cancer Center Hospital East
RECRUITING
South Korea Seoul Seoul National University Hospital
RECRUITING
Poland Katowice Pratia Onkologia Katowice
RECRUITING
Poland Kielce Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Klinika Hematologii i Transplantacji Szpiku
RECRUITING
Poland Skorzewo Aidport Sp z o o
RECRUITING
China Guangzhou Sun Yat Sen University Cancer Center
RECRUITING
Japan Chuo Ku National Cancer Center Hospital
COMPLETED
Show More
Geo Locations

35.6895, 139.69171

25.04776, 121.53185

24.95233, 121.20193

39.91987, 32.85427

39.91987, 32.85427

41.01384, 28.94966

44.49381, 11.33875

37.566, 126.9784

39.9075, 116.39723

30.2341099, 120.164

31.22222, 121.45806

39.14222, 117.17667

35.86224, 139.97732

37.566, 126.9784

50.25841, 19.02754

50.87033, 20.62752

52.3906266, 16.7919124

23.11667, 113.25

35.57779, 139.71685

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.